Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. director Rita Jain received a grant of 1,322 stock options on September 30, 2026. The options were 100% vested and were issued under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. The report lists a transaction price of $12.29 per share and an exercise price of $15.33 per share. The options expire September 30, 2036, and Jain's reported position after the transaction was 1,322 options.
Avalo Therapeutics, Inc. director Kevin Robert Lind received 1,352 stock options on September 30, 2026. The award was 100% vested and was issued under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. Lind's reported post-transaction option position was 1,352.
Avalo Therapeutics, Inc. (AVTX) director Ron M. Philip received 1,109 stock options on September 30, 2026. The options were 100% vested, carry a $15.33 exercise price, and expire September 30, 2036. They were granted under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.
Avalo Therapeutics, Inc. (AVTX) reported that Chief Financial Officer Christopher Ryan Sullivan exercised stock options for 12,394 shares of common stock on September 16, 2026 at an exercise price of $9.88 per share and sold the same number of shares at a weighted-average price of $16.33 per share. The transactions were carried out under a Rule 10b5-1 trading plan adopted on May 18, 2026. Following the option exercise, Sullivan held 83,848 options to purchase additional shares of Avalo Therapeutics common stock.
Avalo Therapeutics, Inc. (AVTX) reported that Chief Financial Officer Christopher Ryan Sullivan exercised stock options for 10,185 shares of common stock at an exercise price of $8.04 per share on September 10, 2026, then sold 10,185 shares of common stock at a weighted average price of $17.6197 per share in multiple transactions. These trades were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026. Following the option exercise, he continued to hold 105,815 options to purchase common stock at $8.04 per share, expiring on January 28, 2035, with the option vesting 25% on January 28, 2026 and the balance in equal monthly installments over the following three years, subject to continued service.
Avalo Therapeutics, Inc. (AVTX) reported that Chief Medical Officer Mittie Doyle exercised stock options for 679 shares of common stock at an exercise price of $8.04 per share and on the same day sold 679 shares of common stock at $20.00 per share. After the option exercise, Doyle held 113,734 stock options directly. All transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025, and the underlying option grant vests 25% on January 28, 2026, with the remainder vesting in equal monthly installments over the following three years.
Avalo Therapeutics, Inc. (AVTX) reported that its Chief Financial Officer, Christopher Ryan Sullivan, exercised stock options and sold common shares in mid-August 2026. He exercised options to acquire a total of 71,852 shares of common stock at an exercise price of $9.88 per share on August 17 and 18, 2026. Over the same two days, he sold 72,725 shares of common stock in open-market transactions at per-share prices reported around $19.85–$20.05, with specific trades occurring within disclosed ranges. The options exercised were part of grants expiring in 2034 and vesting 25% on March 28, 2025 and monthly thereafter. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026.
Avalo Therapeutics, Inc. (AVTX) reported insider transactions by Chief Medical Officer Mittie Doyle. On August 17, 2026, Doyle exercised options to acquire 1,000 shares of common stock at $12.65 per share and sold 1,000 shares at $20.00 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the option exercise, Doyle directly owned 123,750 shares of common stock.
Avalo Therapeutics, Inc. (AVTX) officer Christopher Ryan Sullivan has filed a notice under Rule 144 indicating an intent to sell up to 31,031 shares of common stock through Morgan Stanley Smith Barney. The shares relate to option exercises under a registered plan, including blocks of 25,124 and 5,907 shares for services rendered, with a proposed sale date of 08/18/2026. In the prior three months, Sullivan sold 3,749 shares for proceeds of $74,762.10.
AVTX insider Mittie Doyle notified an intention to sell 5,037 shares of common stock on 08/17/2026, tied to an exercise of stock options, with a referenced value of $98,674.83. The notice also lists recent Rule 10b5-1 sales of AVTX common stock over the prior three months with specified share counts and dollar amounts.